Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 7, pp 1980–1985 | Cite as

High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal

  • Blake D. Babcock
  • Mayada A. Aljehani
  • Brice Jabo
  • Audrey H. Choi
  • John W. Morgan
  • Matthew J. Selleck
  • Fabrizio Luca
  • Elizabeth Raskin
  • Mark E. Reeves
  • Carlos A. Garberoglio
  • Sharon S. Lum
  • Maheswari Senthil
Colorectal Cancer

Abstract

Introduction

Adjuvant chemotherapy is recommended in patients with stage II colon cancer with high-risk features (HRF). However, there is no quantification of the amount of risk conferred by each HRF or the overall survival (OS) benefit gained by chemotherapy based on the risk factor.

Objective

To assess survival benefits associated with adjuvant chemotherapy among stage II colon cancer patients having one or more HRF [T4 tumors, less than 12 lymph nodes examined (< 12LN), positive margins, high-grade tumor, perineural invasion (PNI), and lymphovascular invasion (LVI)].

Methods

Patients diagnosed with stage II colon cancer between 2010 and 2013 were identified from California Cancer Registry. Propensity score weighted all-cause mortality hazard ratios (HR) were calculated for combinations of HRF.

Results

A total of 5160 stage II colon cancer patients were identified, of which 2398 had at least one HRF and 510 of 2398 (21%) received adjuvant chemotherapy. Compared with patients with a single HRF, presence of any 2 or ≥ 3 HRF showed increasingly poorer survival [HR 1.42, 95% confidence interval (CI) 1.16–1.73 and HR 2.50, 95% CI 1.96–3.20, respectively]. Chemotherapy was associated with improved overall survival only among patients with T4 as the single HRF (HR 0.51, 95% CI 0.34–0.78) or combinations involving T4 as T4/< 12 LN (HR 0.31, 95% CI 0.11–0.90), T4/high grade (HR 0.26, 95% CI 0.11–0.61), and T4/LVI (HR 0.16, 95% CI 0.04–0.61).

Conclusions

Not all high-risk features have similar adverse effects on OS. T4 tumors and their combination with other HRF achieve the most survival benefit with adjuvant therapy. Type and number of high-risk features should be taken into consideration when recommending adjuvant chemotherapy in stage II colon cancer.

References

  1. 1.
    Andre T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Quasar Collaborative G, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.CrossRefGoogle Scholar
  3. 3.
    Efficacy of adjuvant fluorouracil and folinic acid in b2 colon cancer. J Clin Oncol. 1999;17(5):1356–63.CrossRefGoogle Scholar
  4. 4.
    Meyers BM, et al. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol. 2016;23(6):418–24.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Casadaban L, et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016;122(21):3277–87.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sato H, et al. High-risk stage II colon cancer after curative resection. J Surg Oncol. 2011;104(1):45–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Artac M, et al. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori. 2014;100(2):143–8.PubMedGoogle Scholar
  8. 8.
    Benson AB 3rd, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.CrossRefPubMedGoogle Scholar
  9. 9.
    Kumar A. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121(4):527–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Park JS, et al. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. J Cancer Res Clin Oncol. 2016;142(9):2051–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Weiss, JM, et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol. 2014;21(6):1781–91.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    National Comprehensive Cancer Network. NCCN Guidelines Colon Cancer (Version 2.2017). National Comprehensive Cancer Network; https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
  13. 13.
    Quah HM, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51(5):503–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Tsikitis VL, et al. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 2014;14:336.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fritz AG. International classification of diseases for oncology: ICD-O. 3rd edn. First revision edn. 2013, Geneva: World Health Organization. viii, 242 pages.Google Scholar
  16. 16.
    Verhoeff SR, et al. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 2016;139(1):187–93.CrossRefPubMedGoogle Scholar
  17. 17.
    Le Voyer TE, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21(15):2912–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Swanson RS, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10(1):65–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Chang GJ, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Santos C, et al. Clinicopathological risk factors of Stage II colon cancer: results of a prospective study. Colorectal Dis. 2013;15(4):414–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Schippinger W, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007;97(8):1021–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Blake D. Babcock
    • 1
  • Mayada A. Aljehani
    • 1
  • Brice Jabo
    • 1
  • Audrey H. Choi
    • 1
  • John W. Morgan
    • 1
  • Matthew J. Selleck
    • 1
  • Fabrizio Luca
    • 1
  • Elizabeth Raskin
    • 1
  • Mark E. Reeves
    • 1
  • Carlos A. Garberoglio
    • 1
  • Sharon S. Lum
    • 1
  • Maheswari Senthil
    • 1
  1. 1.Loma Linda University Cancer CenterLoma LindaUSA

Personalised recommendations